Novo Nordisk A/S
🇩🇰Denmark
- Country
- 🇩🇰Denmark
- Ownership
- Public
- Established
- 1923-01-01
- Employees
- 63.3K
- Market Cap
- $602.2B
- Website
- http://www.novonordisk.com
Injection Site Pain Comparison of Excipient Solutions
- First Posted Date
- 2020-07-22
- Last Posted Date
- 2021-10-19
- Lead Sponsor
- Novo Nordisk A/S
- Target Recruit Count
- 108
- Registration Number
- NCT04482725
- Locations
- 🇳🇱
Novo Nordisk Investigational Site, Groningen, Netherlands
Post-Marketing Surveillance (Special Use-results Surveillance) on Long-term Use With Ozempic®
- Conditions
- Interventions
- First Posted Date
- 2020-07-14
- Last Posted Date
- 2023-11-22
- Lead Sponsor
- Novo Nordisk A/S
- Target Recruit Count
- 3000
- Registration Number
- NCT04469855
- Locations
- 🇯🇵
Novo Nordisk Investigational Site, Yokohama, Kanagawa, Japan
A Research Study to Compare Two Types of Insulin, a New Insulin, Insulin Icodec and an Available Insulin, Insulin Glargine, in People With Type 2 Diabetes Who Have Not Used Insulin Before
Phase 3
Completed
- Conditions
- Interventions
- First Posted Date
- 2020-07-08
- Last Posted Date
- 2024-07-05
- Lead Sponsor
- Novo Nordisk A/S
- Target Recruit Count
- 984
- Registration Number
- NCT04460885
- Locations
- 🇷🇺
Medinet LLC, Saint-Petersburg, Russian Federation
🇺🇸Holston Medical Group, Kingsport, Tennessee, United States
🇺🇸Texas Diab & Endo, P.A., Round Rock, Texas, United States
Clinical Outcomes of NovoSeven® Treatment in Severe Postpartum Haemorrhage - a Study at the University Hospital of Bern
Completed
- Conditions
- Interventions
- First Posted Date
- 2020-06-24
- Last Posted Date
- 2021-01-29
- Lead Sponsor
- Novo Nordisk A/S
- Target Recruit Count
- 225
- Registration Number
- NCT04444856
- Locations
- 🇨🇭
Novo Nordisk Investigational Site, Bern, Switzerland
Post-Marketing Surveillance (Use-results Surveillance) With Esperoct®
- Conditions
- Interventions
- First Posted Date
- 2020-04-03
- Last Posted Date
- 2023-11-28
- Lead Sponsor
- Novo Nordisk A/S
- Target Recruit Count
- 15
- Registration Number
- NCT04334057
- Locations
- 🇯🇵
Novo Nordisk Investigational Site, Yokohama-shi, Kanagawa, Japan
A Research Study, Looking at How Tresiba® Works in People With Type 2 Diabetes in Local Clinical Practice in Russia
- First Posted Date
- 2020-03-19
- Last Posted Date
- 2021-08-23
- Lead Sponsor
- Novo Nordisk A/S
- Target Recruit Count
- 494
- Registration Number
- NCT04315688
- Locations
- 🇷🇺
Novo Nordisk Investigational Site, Vyksa, Russian Federation
SUSTAIN SWITCH: A Research Study to Compare Two Dose Schedules of Semaglutide Taken Once Weekly in People With Type 2 Diabetes
- First Posted Date
- 2020-02-27
- Last Posted Date
- 2022-02-03
- Lead Sponsor
- Novo Nordisk A/S
- Registration Number
- NCT04287179
- Locations
- 🇸🇪
Novo Nordisk Investigational Site, Malmö, Sweden
A Research Study Looking at How Semaglutide Works in People With Type 2 Diabetes in Germany, as Part of Local Clinical Practice (SURE GERMANY)
- First Posted Date
- 2020-02-10
- Last Posted Date
- 2023-03-28
- Lead Sponsor
- Novo Nordisk A/S
- Target Recruit Count
- 789
- Registration Number
- NCT04261933
- Locations
- 🇩🇪
Novo Nordisk Investigational Site, Zwenkau, Germany
A Study to Look at How Safe NNC0472-0147 is in Healthy People and in People With Type 2 Diabetes
Phase 1
Completed
- Conditions
- Interventions
- First Posted Date
- 2020-02-10
- Last Posted Date
- 2022-09-28
- Lead Sponsor
- Novo Nordisk A/S
- Target Recruit Count
- 36
- Registration Number
- NCT04262661
- Locations
- 🇩🇪
Novo Nordisk Investigational Site, Neuss, Germany
First Research Study to Look at How Two Medicines, NNC0480-0389 and Semaglutide, Work Together in Healthy People, in People With High Body Weight and in People With Diabetes
Phase 1
Completed
- Conditions
- Interventions
- First Posted Date
- 2020-02-06
- Last Posted Date
- 2023-11-13
- Lead Sponsor
- Novo Nordisk A/S
- Target Recruit Count
- 152
- Registration Number
- NCT04259801
- Locations
- 🇳🇱
Novo Nordisk Investigational Site, Groningen, Netherlands
© Copyright 2024. All Rights Reserved by MedPath